Магнитно-резонансная томография при диагностике метастазов рака молочной железы в головной мозг (краткий обзор литературы)
https://doi.org/10.24835/1607-0763-1174
Аннотация
Рак молочной железы занимает 1-е место в структуре онкологической заболеваемости и смертности у женского населения в Российской Федерации и является второй по частоте метастазирования первичной солидной злокачественной опухолью после рака легких, а встречаемость этих, часто смертельных поражений в настоящее время увеличивается после улучшения системного лечения.
При этом прогноз пациенток, у которых развивается метастатическое поражение головного мозга, обычно неблагоприятный, так как немногие из них живут дольше 1 года.
Цель исследования: проанализировать последние исследования, относящиеся к вопросам применения магнитно-резонансная томографии при диагностике метастазов рака молочной железы в головной мозг.
Заключение. При наличии характерных результатов МРТ-исследований, указывающих на наличие возможных первичных глиом головного мозга, а не метастазов, необходимо хирургическое вмешательство (биопсия) для гистопатологических исследований с целью окончательного установления диагноза основного заболевания.
Об авторах
Г. А. Паньшин
ФГБУ “Российский научный центр рентгенорадиологии” Минздрава России
Россия
Россия
Паньшин Георгий Александрович – доктор медицинских наук, профессор, главный научный сотрудник
117997 ГСП-7, Москва, ул. Профсоюзная, д. 86
тел.: +7-495-333-93-41
Н. В. Нуднов
ФГБУ “Российский научный центр рентгенорадиологии” Минздрава России
Россия
Россия
Нуднов Николай Васильевич – доктор медицинских наук, профессор, заместитель директора по научной работе, заведующий НИО комплексной диагностики заболеваний и радиотерапии
117997 ГСП-7, Москва, ул. Профсоюзная, д. 86
Список литературы
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ “НМИЦ радиологии” Минздрава России”. 2019. 250 с. ISBN 978-5-85502-251-3. https://oncology-association.ru/wp-content/uploads/2020/09/2018.pdf
2. Dawood S., Gonzalez-Angulo A.M., Albarracin C. et al. Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010; 116 (13): 3084–3092. http://doi.org/10.1002/cncr.25115
3. Niikura N., Hayashi N., Masuda N. et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res. Treat. 2014; 147 (1): 103–112. http://doi.org/10.1007/s10549-014-3090-8
4. Jang G., Lee S.S., Ahn J.H. et al. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Res. Treat. 2011; 128 (1): 171–177. http://doi.org/10.1007/s10549-011-1526-y
5. Cho S.Y., Choi H.Y. Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. Am. J. Clin. Pathol. 1980; 73 (2): 232–234. http://doi.org/10.1093/ajcp/73.2.232
6. DiStefano A., Yong Yap Y., Hortobagyi G.N., Blumenschein G.R. The natural history of breast cancer patients with brain metastases. Cancer. 1979; 44 (5): 1913–1918. http://doi.org/10.1002/1097-0142(197911)44:5<1913::aid-cncr2820440554>3.0.co;2-d
7. Engel J., Eckel R., Aydemir U. et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55 (5): 1186–1195. http://doi.org/10.1016/s0360-3016(02)04476-0
8. Arslan U.Y., Oksuzoglu B., Aksoy S. et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast. 2011; 20 (6): 562–567. http://doi.org/10.1016/j.breast.2011.07.017
9. Kim H.J., Im S.A., Keam B. et al. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J. Neurooncol. 2012; 106 (2): 303–313. http://doi.org/10.1007/s11060-011-0664-8
10. Stupp R., Mason W.P., van den Bent M.J. et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005; 352 (10): 987–996. http://doi.org/10.1056/NEJMoa043330
11. Dawood S., Gonzalez-Angulo A.M., Albarracin C. et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010; 116 (13): 3084–3092. http://doi.org/10.1002/cncr.25115
12. Niikura N., Hayashi N., Masuda N. et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res. Treat. 2014; 147 (1): 103–112. http://doi.org/10.1007/s10549-014-3090-8
13. Jang G., Lee S.S., Ahn J.H. et al. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Res. Treat. 2011; 128 (1): 171–177. http://doi.org/10.1007/s10549-011-1526-y
14. Soffietti R., Cornu P., Delattre J.Y. et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur. J. Neurol. 2006; 13(7): 674–681. http://doi.org/10.1111/j.1468-1331.2006.01506.x
15. Hadjipanteli A., Doolan P., Kyriacou E., Constantinidou A. Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications. Cancer Manag. Res. 2020; 12: 9953–9964. http://doi.org/10.2147/CMAR.S252801
16. Mystakidou K., Kouloulias V., Tsilika E. et al. Is early recognition of radiologically silent brain metastasis from breast cancer beneficial? A retrospective study of 22 cases. Breast Cancer. 2004; 11 (3): 276–281. http://doi.org/10.1007/BF02984549
17. Matsuo S., Watanabe J., Mitsuya K. et al. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res Treat. 2017; 162 (1): 169–179. http://doi.org/10.1007/s10549-017-4107-x
18. Ono M., Ando M., Yunokawa M. et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int. J. Clin. Oncol. 2009; 14 (1): 48–52. http://doi.org/10.1007/s10147-008-0797-8
19. El Zawawy S.F. 236O_PRMONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Ann. Oncol. 2017; 28 (Suppl. 5): 1339–1345. http://doi.org/10.1093/annonc/mdx075
20. Azim H.A., Abdel-Malek R., Kassem L. Predicting brain metastasis in breast cancer patients: stage versus biology. Clin. Breast Cancer. 2018; 18 (2): e187–195. http://doi.org/10.1016/j.clbc.2017.08.004
21. Walker R., Kessar P., Blanchard R. et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J. Magn. Reson. Imaging. 2000; 11 (4): 343–350. http://doi.org/10.1002/(SICI)1522-2586(200004)11:4<343::AIDJMRI1>3.0.CO;2-P
22. Ghezzi P., Magnanini S., Rinaldini M. et al. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA. 1994; 271 (20): 1587–1592. http://doi.org/10.1001/jama.1994.03510440047031
23. U.S. National Library of Medicine [Internet]: Maryland (USA): National Institutes of Health. Screening magnetic resonance imaging of the brain in patients with breast cancer. 2000 – Identifier NCT04030507. Bethesda, Maryland (United States; July 2019. Available from https://clinicaltrials.gov/ct2/show. Accessed July 31, 2020.
24. Lower E.E., Khan S., Kennedy D., Baughman R.P. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer Targets Ther. 2017; 9: 515–520. http://doi.org/10.2147/BCTT.S137709
25. Hoefnagel L.D.C., van de Vijver M.J., van Slooten H.J. et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010; 12: 5. http://doi.org/10.1186/bcr2645
26. Williams N., Varadan V., Vadodkar A. et al. Intrinsic subtypes and MRI patterns in brain metastasis associated with breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9–13; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2015; 75 (9, Suppl.): Abstract nr P6-16-03.
27. Ahn S.J., Park M., Bang S. et al. Apparent diffusion coefficient histogram in breast cancer brain metastases may predict their biological subtype and progression. Sci. Rep. 2018; 8 (1): 1–7. http://doi.org/10.1038/s41598-018-28315-y
28. Bender E.T., Tomé W.A. Distribution of brain metastases: implications for non-uniform dose prescriptions. Br. J. Radiol. 2011; 84 (1003): 649–658. http://doi.org/10.1259/bjr/30173406
29. Quattrocchi C.C., Errante Y., Gaudino C. et al. Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. J. Neurooncol. 2012; 110 (1): 79–87. http://doi.org/10.1007/s11060-012-0937-x
30. Kyeong S., Jin Cha Y., Gwe Ahn S. et al. Subtypes of breast cancer show different spatial distributions of brain metastases. PLoS One. 2017; 12 (11): 1–10. http://doi.org/10.1371/journal.pone.0188542
31. Rostami R., Mittal S., Rostami P. et al. Brain metastasis in breast cancer: a comprehensive literature review. J. Neurooncol. 2016; 127 (3): 407–414. http://doi.org/10.1007/s11060-016-2075-3
32. Schouten L.J., Rutten J., Huveneers H.A.M., Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94 (10): 2698–2705. http://doi.org/10.1002/cncr.10541
33. Ramakrishna N., Temin S., Chandarlapaty S. et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014; 32 (19): 2100–2108. http://doi.org/10.1200/JCO.2013.54.0955
34. Huynh P.T., Lemeshko S.V., Mahoney M.C. et al. ACR Appropriateness Criteria ® Stage I breast carcinoma. J. Am. Coll. Radiol. 2016; 13 (11): e53–57. http://doi.org/10.1016/j.jacr.2016.09.024
35. Miller K.D., Weathers T., Haney L.G. et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol. 2003; 14 (7): 1072–1077. http://doi.org/10.1093/annonc/mdg300
36. Niwińska A., Tacikowska M., Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int. J. Radiat. Oncol. Biol. Phys. 2010; 77 (4): 1134–1139. http://doi.org/10.1016/j.ijrobp.2009.06.030
37. Brown P.D., Jaeckle K., Ballman K.V. et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016; 316 (4): 401–409. http://doi.org/10.1001/jama.2016.9839
38. Metro G., Foglietta J., Russillo M. et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 2011; 22 (3): 625–630. http://doi.org/10.1093/annonc/mdq434
39. Plunkett R.J., Barone T.A., Brady W.E. et al. Do brain mets grow while you wait? A volumetric natural history assessment of brain metastases from time of diagnosis to gamma knife treatment. J. Clin. Neurosci. 2019; 68: 117–122. http://doi.org/10.1016/j.jocn.2019.07.019
40. Shaw E., Scott C., Souhami L. et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 1999; 47 (2): 2 91–298. http://doi.org/10.1016/S0360-3016(99)00507-6
41. Kim S.Y., Kim J.S., Park H.S. et al. Screening of brain metastasis with limited Magnetic Resonance Imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J. Korean Med. Sci. 2005; 20 (1): 121–126. http://doi.org/10.3346/jkms.2005.20.1.121
42. Li P.C., Cagney D.N., Martin A. et al. Brain metastases in patients with breast cancer versus non–small cell lung cancer: comparison of an unscreened versus a screened population. Int. J. Radiat. Oncol. 2017; 99 (2): E30. https://doi.org/10.1016/j.ijrobp.2017.06.662
43. Matsuo S., Watanabe J., Mitsuya K. et al. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res. Treat. 2017; 162 (1): 169–179. http://doi.org/10.1007/s10549-017-4107-x
44. Azim H.A., Abdel-Malek R., Kassem L. Predicting brain metastasis in breast cancer patients: stage versus biology. Clin. Breast Cancer. 2018; 18 (2): e187–195. http://doi.org/10.1016/j.clbc.2017.08.004
45. Lower E.E., Khan S., Kennedy D., Baughman R.P. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer Targets Ther. 2017; 9: 515–520. http://doi.org/10.2147/BCTT.S137709
46. Curtit E., Nerich V., Mansi L. et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013; 18 (6): 667–674. http://doi.org/10.1634/theoncologist.2012-0350
47. Kuwabara T., Yoshikawa K. Physical performance testing of digital breast tomosynthesis. Proc. SPIE Med. Imaging. 2015. http://doi.org/10.1117/12.2081079
48. Thompson A.M., Jordan L.B., Quinlan P. et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010; 12: 6. http://doi.org/10.1186/bcr2771
49. Simmons C., Miller N., Geddie W. et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann. Oncol. 2009; 20 (9): 1499–1504. http://doi.org/10.1093/annonc/mdp028
50. Lindström L.S., Karlsson E., Wilking U.M. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 2012; 30 (21): 2601–2608. http://doi.org/10.1200/JCO.2011.37.2482
51. Laakmann E., Witzel I., Scriba V. et al. Radiological patterns of brain metastases in breast cancer patients: a subproject of the german brain metastases in breast cancer (BMBC) registry. Int. J. Mol. Sci. 2016; 17 (10): 10. http://doi.org/10.3390/ijms17101615
52. Hengel K., Sidhu G., Choi J. et al. Attributes of brain metastases from breast and lung cancer. Int. J. Clin. Oncol. 2013; 18 (3): 396–401. http://doi.org/10.1007/s10147-012-0392-x
53. Bender E.T., Tomé W.A. Distribution of brain metastases: implications for non-uniform dose prescriptions. Br. J. Radiol. 2011; 84 (1003): 649–658. http://doi.org/10.1259/bjr/30173406
54. Kyeong S., Jin Cha Y., Gwe Ahn S. et al. Subtypes of breast cancer show different spatial distributions of brain metastases. PLoS One. 2017; 12 (11): 1–10. http://doi.org/10.1371/journal.pone.0188542
55. Yeh R.H., Yu J.C., Chu C.H. et al. Distinct MR imaging features of triple-negative breast cancer with brain metastasis. J. Neuroimaging. 2015; 25 (3): 474–481. http://doi.org/10.1111/jon.12149
56. Uematsu T., Kasami M., Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009; 250 (3): 638–647. http://doi.org/10.1148/radiol.2503081054
57. Béresová M., Larroza A., Arana E. et al. 2D and 3D texture analysis to differentiate brain metastases on MR images: proceed with caution. Magn. Reson. Mater. Physics. Biol. Med. 2018; 31 (2): 285–294. http://doi.org/10.1007/s10334-017-0653-9
58. Zakaria R., Das K., Bhojak M. et al. The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis. Cancer Imaging. 2014; 14(1): 1–8. http://doi.org/10.1186/1470-7330-14-1
59. Taneja S., Jena A., Goel R. et al. Simultaneous whole-body 18F-FDG PET-MRI in primary staging of breast cancer: A pilot study. Eur. J. Radiol. 2014; 83 (12): 2231–2239. http://doi.org/10.1016/j.ejrad.2014.09.008
60. Schmidt G.P., Baur-Melnyk A., Haug A. et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur. J. Radiol. 2008; 65 (1): 47–58. http://doi.org/10.1016/j.ejrad.2007.10.021
Рецензия
Для цитирования:
Паньшин Г.А., Нуднов Н.В. Магнитно-резонансная томография при диагностике метастазов рака молочной железы в головной мозг (краткий обзор литературы). Медицинская визуализация. 2022;26(4):23-31. https://doi.org/10.24835/1607-0763-1174
For citation:
Panshin G.A., Nudnov N.V. Magnetic resonance imaging in the diagnosis of breast cancer metastases in the brain (a brief review of the literature). Medical Visualization. 2022;26(4):23-31. (In Russ.) https://doi.org/10.24835/1607-0763-1174
Просмотров:
681
Послать статью по эл. почте 